PolyPid Ltd
PYPD3.546USD
+0.136+4.00%
Market hours （ET）Quotes delayed by 15 min
36.14MMarket Cap
LossP/E TTM
More Details of PolyPid Ltd Company
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Company Info
Ticker SymbolPYPD
Company namePolyPid Ltd
IPO dateJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad
Number of employees57
Security typeOrdinary Share
Fiscal year-endJun 26
Address18 Hasivim Street, P.O Box 7126
CityPETAH TIKVA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code4917002
Phone972747195700
Websitehttps://www.polypid.com
Ticker SymbolPYPD
IPO dateJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Dr. Shaul Mukhtar, Ph.D.
Dr. Shaul Mukhtar, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Dalit Hazan
Ms. Dalit Hazan
Senior Vice President - Research and Development and Regulatory Affairs
Senior Vice President - Research and Development and Regulatory Affairs
--
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Shareholders
Shareholders
Proportion
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Shareholder Types
Shareholders
Proportion
Venture Capital
19.88%
Hedge Fund
19.57%
Holding Company
10.87%
Individual Investor
9.02%
Corporation
5.77%
Investment Advisor/Hedge Fund
4.75%
Private Equity
4.54%
Investment Advisor
0.28%
Research Firm
0.02%
Other
25.31%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
41
7.61M
74.69%
+1.40M
2025Q1
42
7.66M
75.16%
+942.60K
2024Q4
44
5.48M
65.20%
+1.87M
2024Q3
50
4.47M
69.98%
+1.49M
2024Q2
58
3.43M
73.51%
+1.59M
2024Q1
59
3.33M
71.29%
+2.56M
2023Q4
54
443.78K
34.10%
+80.67K
2023Q3
57
479.04K
37.01%
+97.48K
2023Q2
57
472.86K
36.65%
+91.51K
2023Q1
59
332.36K
28.62%
+89.40K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Aurum Ventures M.K.I.
2.03M
19.88%
+11.34K
+0.56%
Feb 26, 2025
Centaurus Investments Limited
1.11M
10.87%
+475.10K
+75.12%
Dec 31, 2024
Rosalind Advisors, Inc.
1.02M
9.99%
--
--
Mar 31, 2025
Nir (Yehuda)
613.91K
6.02%
+62.60K
+11.36%
Mar 31, 2025
Hewlett Fund, L.P.
587.92K
5.77%
+338.44K
+135.66%
Feb 26, 2025
Triple Gate Capital, LP
465.84K
4.57%
+465.84K
--
Feb 26, 2025
AIGH Capital Management, LLC.
510.95K
5.01%
-507.07K
-49.81%
Mar 31, 2025
Worth Venture Partners, LLC
429.43K
4.21%
+153.81K
+55.80%
Mar 31, 2025
Lukach (Aharon)
299.55K
2.94%
-5.64K
-1.85%
Mar 31, 2025
Dafna Capital Management, LLC
291.27K
2.86%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Date
Type
Ratio
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
